#2 - AbCellera Biologics (NASDAQ:ABCL)
Artificial intelligence boosts the underlying thesis for AbCellera Biologics, Inc. (NASDAQ: ABCL). The company has an AI-powered engine that it uses for antibody drug discovery and development. The company is looking for antibodies from natural immune responses, which are pre-enriched for antibodies.
Cash is always a concern for clinical-stage biotech companies, but it appears to be less of a concern for AbCellera. The company has five years of funding for its operations at its current run rate. And it is partnering with larger companies to get its pipeline candidates through the clinical trial stage.
Despite the fact that the company will not be profitable for several years, the AbCellera analyst ratings on MarketBeat give ABCL stock a Buy rating with a 225.75% upside, making it one of the largest potential gainers for stocks under $20.
About AbCellera Biologics
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Read More - Current Price
- $2.85
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $8.67 (204.1% Upside)
